BPI viper antivenom

BPI viper antivenom is a lyophilized (freeze-dried) monospecific F(ab)2 fragment-based equine-derived immunoglobulin preparation developed for the treatment of envenoming by Russell’s viper (*Daboia siamensis*) in Myanmar. It was developed as part of a collaborative initiative to improve access to effective snakebite therapy in regions with limited electrification and healthcare infrastructure. The product contains purified F(ab)2 antibody fragments that specifically bind and neutralize Russell’s viper venom toxins, facilitating their redistribution away from target tissues and elimination from the body. The mechanism of action involves direct binding to venom components, thereby preventing or reversing toxic effects such as coagulopathy and tissue damage. The drug is produced using hyper-immune horse plasma at GMP-compliant facilities operated by Burma Pharmaceutical Industry (BPI). It has replaced previous liquid formulations due to improved stability and ease of distribution[4][5][6][10].

Brand names

BPI viper antivenom

Other names

Lyophilized BPI viper antivenomfreeze-dried anti-snake venom (BPI)monospecific lyophilised F(ab)2 antivenom (Viper antivenom BPI)